Cytek Biosciences, Inc. Common Stock (CTKB) Stock Price
CTKBStock
$5.25+30.60%52W
Market Cap$682.41M
P/E—
PEG Ratio—
Div yield—
Beta1.16
CTKB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)3.73%
Price vs S&P 500 (4W)0.76%
VGM Score55.64
CTKB Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.02 | -$0.03 | -55.00%(-$0.01) | |
| Q1 2026 | -$0.08 | -$0.10 | -20.00%(-$0.02) | |
| Q4 2025 | $0.01 | -$0.29 | -2014.67%(-$0.30) | |
| Q3 2025 | $0.01 | -$0.00 | -103.00%(-$0.01) | |
| Q2 2025 | -$0.01 | -$0.01 | +52.53%(+$0.01) |
CTKB Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
4.00
4.00
4.00
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
CTKBCytek Biosciences, Inc. Common Stock | C | C | B | 3.3x | 16.8% | 53.2% | -21.6% | $5.25 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
About Cytek Biosciences, Inc. Common Stock
Cytek Biosciences develops full-spectrum flow cytometry systems that enable high-resolution, sensitive cell analysis at a lower cost than conventional technologies. Its Aurora and Northern Lights platforms leverage advanced fluorescence detection to deliver superior analytical power and flexibility for research and diagnostics applications. The company generates the majority of its revenue from the United States.